JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (11): 55-59.doi: 10.6040/j.issn.1671-7554.0.2014.347

Previous Articles     Next Articles

Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer

ZHANG Miaoci, LI Ping, HA Minwin   

  1. Department of Oncology, the First Affiliated Hospital of Liaoning Medical University, Jinzhou 121000, Liaoning, China
  • Received:2014-05-28 Published:2014-11-10

PDF (PC)

186

Abstract: Objective To evaluate the efficacy and safety of recombinant human endostatin(endostar) in combination with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer. Methods A total of 64 patients with platinum-resistant recurrent ovarian cancer were randomly divided into the experimental group (n=33) and control group (n=31). The experimental group received endostar plus gemcitabine while the control group gemcitabine regimen alone. The efficacy, adverse reactions and quality of life were compared. Results Statistically significant differences were observed in the objective response rate, disease control rate and median progression-free survival between the experimental group and control group (39.3% vs 16.1%,75.8% vs 41.9%, 6.5 months vs 3.1 months, P<0.05). No statistically significant differences were found in the median overall survival (13.7 vs 10.9 months), adverse reactions and quality of life between the two groups (P>0.05). Conclusion Endostar in combination with gemcitabine significantly improves short-term effect and median progression-free survival in patients with platinum-resistant recurrent ovarian cancer without increasing the incidence of adverse effects.

Key words: Chemotherapy, adjuvant, Platinum-resistant recurrent ovarian cancer, Recombinant human endostatin, Gemcitabine

CLC Number: 

  • R737.31
[1] Mantia-Smaldone G M, Edwards R P,Vlad A M. Targeted treatment of recurrent platinum-resistant ovarian cancer:current and emerging therapies[J]. Cancer Manag Res, 2011, 3:25-38. DOI:10.2147/CMR.S8759.
[2] Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer:The AURELIA Open-Label Randomized Phase III Trial [J]. J Clin Oncol, 2014, 32(13):1302-1308.
[3] Matsuo K, Lin Y G, Roman L D, et al. Overcoming platinum resistance in ovarian carcinoma [J]. Expert Opin Investig Drugs, 2010, 19(11):1339-1354.
[4] Naumann R W, Coleman R L. Management strategies for recurrent platinum-resistant ovarian cancer [J]. Drugs, 2011, 71(11):1397-1412.
[5] Barber E L, Zsiros E, Lurain J R, et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer [J]. J Gynecol Oncol, 2013, 24(3):258-264.
[6] Davis A, Tinker A V, Friedlander M. “Platinum resistant” ovarian cancer:what is it, who to treat and how to measure benefit ?[J] Gynecol Oncol, 2014, 133(3):624-631.
[7] Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer:current options [J]. Onco Targets Ther, 2013, 6:107-118 . DOI:10.2147/OTT.S30238.
[8] Tillmanns T D, Lowe M P, Walker M S, et al. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma [J]. Gynecol Oncol, 2013, 128(2):221-228.
[9] Folkman J. Tumor angiogenesis:therapeutic implications [J]. N Engl J Med, 1971, 285(21):1182-1186.
[10] Coleman R L, Brady W E, McMeekin D S, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2011, 122(1):111-115.
[11] 秦叔逵, 刘秀峰, 王琳, 等. 重组人血管内皮抑素与化疗联合治疗肺外晚期恶性肿瘤的临床研究[J]. 临床肿瘤学杂志, 2007, 12(10):728-735. QIN Shukui, LIU Xiufeng, WANG Lin, et al. Clinical study of endostar combined with chemotherapy for the multiple kind of advanced malignancies except lung cancer[J]. Chinese Clinical Oncology, 2007, 12(10):728-735.
[12] Jain R K. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy [J]. Science, 2005, 307(5706):58-62.
[13] Xu W J, Huang C, Wang J, et al. Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states[J]. Chin Med J (Engl), 2011, 124(18):2883-2889.
[14] 阿力木江·赛提瓦尔地, 张涛, 帕提古丽·阿尔西丁, 等. 重组人血管内皮抑素联合吉西他滨及顺铂治疗晚期非小细胞肺癌的临床分析[J]. 山东大学学报:医学版, 2013, 51(3):95-98. ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, et al. Clinical analysis of recombinant human endostatin combined with gemcitabine and cisplatin therapy in advanced non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2013, 51(3):95-98.
[15] 刘春玲, 袁静, 顾国民. 重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌临床疗效[J]. 山东大学学报:医学版, 2011, 49(9):122-126. LIU Chunling, YUAN Jing, GU Guomin. Clinical observation of recombinant human endostatin combined with chemotherapy for advanced non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2011, 49(9):122-126.
[16] 赵长林, 唐磊, 殷江霞, 等. 重组人血管内皮抑素联合GC方案治疗晚期非小细胞肺癌1例[J]. 中国肺癌杂志, 2009, 12(5):460-462. ZHAO Changlin, TANG Lei, YIN Jiangxia, et al. Endostar combined GC in the treatment of advanced non-small cell lung cancer [J]. Chin J Lung Cancer, 2009, 12(5):460-462.
[17] 王金万, 孙燕, 刘永煜, 等. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC 随机、 双盲、对照、多中心Ⅲ期临床研究[J]. 中国肺癌杂志, 2005, 8 (4):283-290. WANG Jinwan, SUN Yan, LIU Yongyu, et al. Results of randomized, multicenter, double blind phase Ⅲ trail of rh-endostatin (YH-16) in treatment of advanced nonsmall cell lung cancer patients [J]. Chin J Lung Cancer, 2005, 8(4):283-290.
[18] Zhang D W, Li H L, Yao Q, et al. The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma[J]. J Int Med Res, 2010, 38(1):111-126.
[19] Van Moorselaar R J, Voest E E. Angiogenesis in prostate cancer:its role in disease progression and possible therapeutic approaches[J]. Mol Cell Endocrinol, 2002, 197(1-2):239-250.
[20] Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma[J]. Blood, 2000, 96(1):282-287.
[21] Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment[J]. Crit Rev Ther Drug Carrier Syst, 2007, 24(5):445-492.
[22] 谢伟敏, 黄银梅. 血管内皮抑素治疗恶性肿瘤的研究进展[J]. 中国癌症防治杂志, 2009, 1(3):279-281. XIE Weimin, HUANG Yinmei. Advances in research on endostatin in the treatment of malignant tumor[J]. Chin J of Oncol Prev and Treat, 2009, 1(3):279-281.
[1] YIN Lei, YIN Rui, LI Wenjia, LIU Shuai, L(¨overU)Jiaju. CYLD improves bladder cancer gemcitabine chemosensitivity via suppressing autophagy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 1-6.
[2] SUN Jie, MU Xiaoyan, DONG Xueli. Combinational and sequential effect of sunitinib and gemcitabine on K-RAS mutant A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 45-49.
[3] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
[4] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
[5] LIU Chun-ling, YUAN Jing, GU Guo-min. Clinical observation of recombinant human endostatin combined with chemotherapy for advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 122-.
[6] YANG Ning, HAN Jun-qing, SHENG Wei. Relationship of expressions of RRM1 and ERCC1 proteins with  response and prognosis in advanced NSCLC patients receiving  cisplatin combined with gemcitabine chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 89-93.
[7] JIANG Xiao-dong1,2, DAI Peng2, WU Jin2, SONG Da-an2, YU Jin-ming3. Weekly recombinant human endostatin as a hypoxic tumor cell radio sensitizer combined with radiotherapy for non-small-cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 108-.
[8] WANY Yang1，HU Likuan1，WANY Jiao1，WANY Cuihong1,ZHANG Yong2. Effect of YH-16 on blood pressure, coagulation and fibrinolytic-function of malignant tumors treated with three-dimensional conformal radiotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(3): 131-.
[9] LI Hong-mei,LI Hai-xia,LIU Kei-wei,WANG Xiu-mei. Three chemotherapy regimens including cisplatin for advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(5): 499-502.
[10] LI Yu-liang,WANG Yong-zheng,WANG Xiao-hua,ZHANG Fu-jun,ZHU Li-dong,ZHANG Wang-ming,LI Zheng,LI Zhen-jia,ZHANG Kai-xian. I implantation combined with Gemcitabine in the treatment of advanced pancreatic cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(4): 393-396.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd